Insights From an Integrated Physiologically Based Pharmacokinetic Model for Brain Penetration

Area of Science:

• Pharmacokinetics and Drug Metabolism
• Neuroscience
• Computational Biology

Background:

• Physiologically based pharmacokinetic (PBPK) models are crucial for predicting drug distribution in the central nervous system (CNS).
• Accurate estimation of blood-brain barrier (BBB) permeability and active transport is essential for effective CNS drug development.
• Existing models often require refinement for complex transport mechanisms and physiological barriers.

Purpose of the Study:

• To develop and validate a PBPK model for predicting brain exposure profiles of CNS-penetrating compounds.
• To present improved methodologies for determining critical input parameters, including passive permeability and active transport.
• To simplify the PBPK model into a predictive equation for steady-state brain-to-plasma ratios.

Main Methods:

• Development of a PBPK model integrating BBB transport parameters.
• Linear regression analysis to estimate passive BBB permeability from in vivo brain uptake data.
• Novel in vitro assay analysis to determine active transport parameters, accounting for paracellular transport and unstirred water layers.
• Validation of the PBPK model for both rate-limited and effluxed compounds with high passive permeability.

Main Results:

• The integrated PBPK model accurately captures concentration profiles for various compound types.
• Improved methods provide reliable estimates for passive permeability and active transport parameters.
• A simplified equation effectively describes steady-state brain-to-plasma ratios.
• The model demonstrates rapid distribution for many compounds, indicating they are not rate-limited.

Conclusions:

• The developed PBPK model and refined parameter estimation methods enhance the prediction of CNS drug exposure.
• The simplified equation offers a valuable tool for estimating brain penetration in early drug discovery.
• This approach facilitates informed decisions regarding compound selection and optimization for CNS targets.